Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Synergy Pharmaceuticals Inc. (SGYP - Snapshot Report) recently announced that it will be raising funds through an underwritten public offering. Synergy Pharma intends to sell $90 million of its common stock through an underwritten public offering. The aggregate value may amount to $103.5 million if the underwriters exercise their over-allotment option fully.

We expect the fund raised from the public offering to be invested in the company’s research and development efforts. Synergy Pharma has several pipeline candidates in its pipeline.

The lead candidate at Synergy Pharma is plecanatide. In Jan 2013, Synergy Pharma reported positive data from a phase IIb/III study on plecanatide, being developed for the treatment of patients suffering from chronic idiopathic constipation (CIC).

Moreover, in Dec 2012, Synergy Pharma initiated a phase IIb study with plecanatide for the treatment of patients suffering from constipation-predominant irritable bowel syndrome (IBS-C). The trial is evaluating the average change in complete spontaneous bowel movements (CSBMs) during the course of the therapy (12 weeks) in comparison to their baseline weekly CSBM rate established during the screening phase of the study.

Synergy Pharma also has SP-333 in its pipeline. The company has completed a phase I placebo-controlled, dose-escalating, single-dose study on the candidate, for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC). In Jan 2013, Synergy Pharma initiated a phase I multiple-ascending-dose clinical study on SP-333 in healthy volunteers.

Synergy Pharma, a biopharmaceutical company, currently carries a Zacks Rank #4 (Sell). However, other biopharmaceutical stocks such as UCB (UCBJF), Athersys Inc. (ATHX - Snapshot Report) and Celgene Corporation (CELG - Analyst Report) currently look more attractive. While UCB and Athersys carry a Zacks Rank #1 (Strong Buy), Celgene carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CELL THERAPE CTIC 3.33 +11.37%
CANADIAN SOL CSIQ 29.64 +9.45%
LORUS THERAP LRUSF 0.50 +8.77%
ZIOPHARM ONC ZIOP 3.80 +8.26%
ENANTA PHARM ENTA 36.82 +7.38%